Ablexis licenses antibodies for CAR-T development
The clinical-stage biotechnology company Allogene has licensed Ablexis’ antibodies for the use of CAR-T therapy research and development.
Archives for January 3, 2019
AC Immune inks $1.7bn deal with Lilly, strategic partnership with WuXi
Eli Lilly and Company and AC Immune have signed an agreement for the research and development of tau aggregation inhibitor small molecules, and AC Immune signed a strategic partnership with WuXi biologics.
US FDA approves vaccine protecting against six diseases
Sanofi and MSD received approval for a vaccine that protects children against diseases caused by six infectious agents.
Contaminated losartan sees 3.2m tablets recalled in Taiwan
Taiwan’s Food and Drug Administration announced that Siu Guan will instigate a recall of 11 batches of blood pressure tablets.
CRO industry still plagued by CRA turnover: Report
Most CROs are struggling with employee retention, a challenge not new to the industry, which has seen turnover levels at or above 20% for seven of the last 10 years, according to a recent report.
Guest column
Looking back, looking forward: The days of process driving clinical trials are just about over
This time next year, I hope I can write a column with the headline “2019: The year of cooperation and communication in the clinical trial industry.” We’ve made some exciting progress toward that end in 2018. Now it’s time to take it to the next level.
BMS begins year with $74bn Celgene acquisition
BMS announced that it will merge with Celgene, bolstering its oncology and immunology/inflammation franchises.